This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine.

We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry.

First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the data actually showed, why the comparison was misleading, how trial design and dosing matter, and why Phase 1 results should never be treated as superiority claims.

Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk. We discuss how this pill differs from compounded oral semaglutide, why its pricing strategy is so disruptive, and what this launch means for people who have avoided injectable medications. We also explore how direct-to-consumer access, telehealth partnerships, and retail pharmacy distribution signal a broader shift in how obesity care is being delivered.

Finally, we address the most ironic—and uncomfortable—story of the week: manufacturing quality concerns involving branded Wegovy pens, reported to include biological particulate matter, at the same time Novo Nordisk continues a years-long public and legal campaign against compounded GLP-1 medications on safety grounds. We discuss FDA inspection history, the acquisition of Catalent, and why credibility depends on consistency—especially when millions of patients are paying close attention.

This episode isn’t anti-pharma or pharma-friendly. It’s patient-first.
And it asks a simple question: Who do we trust when science, marketing, access, and manufacturing all collide at once?

Episode Timestamps

00:00 — Why this first episode of 2026 matters
02:10 — Hair found in Wegovy pens and why patients notice hypocrisy
06:15 — Arrowhead trial headlines vs. what the data actually shows
11:40 — Why tirzepatide dosing and trial design matter
17:30 — What INHBE targeting may actually be good for (and what it’s not)
21:45 — Sponsor: SHED and access pathways for obesity care
25:10 — Oral Wegovy officially launches: what’s different this time
30:20 — How the Wegovy pill works and why bioavailability matters
35:40 — Pricing, telehealth, Costco, and direct-to-consumer access
41:50 — Why pills lower barriers for millions of patients
46:10 — Manufacturing quality, Catalent, and FDA citations
52:30 — Why safety arguments against compounding are being scrutinized
58:40 — Zooming out: access, accountability, and patient trust
1:02:00 — Final thoughts and what to watch next

Topics Covered

GLP-1 trial hype vs. real-world context
Phase 1 data limitations and headline inflation
Tirzepatide dosing and misleading comparisons
Oral Wegovy vs. compounded oral semaglutide
GLP-1 pill pricing and insurance implications
Direct-to-consumer pharma and telehealth disruption
Manufacturing quality and FDA oversight
Compounding pharmacies and healthcare system resilience
Patient trust, transparency, and credibility in obesity medicine

Useful Links & Resources

On The Pen Links & Advocacy: https://otplinks.com
Sponsor – SHED (use code OTP25): https://tryshed.com
FDA Drug Safety & Recalls: https://www.fda.gov/drugs
Follow On The Pen:
- YouTube: https://youtube.com/@onthepen
- Substack: https://onthepen.substack.com

Support the Show

If this episode helped you better understand what’s really happening in obesity medicine:

Leave a 5-star rating and review
Hit Subscribe so you don’t miss future episodes
Join us live Mondays, Wednesdays, and Fridays at 12pm Eastern on YouTube

Patients deserve clarity.
That’s what we’re here for.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Wegovy Pens Recalled & Wegovy Pill Launch